Dr. Silverman has over 20 years of successful entrepreneur experience in new biotechnology research, development and commercialization and a world leader in methane conversion technologies. Dr. Silverman was recruited to Aromyx as CEO in 2018 to lead a successful recapitalization and relaunch of the company. Before joining Aromyx he was Founder and Chief Technology Officer of Calysta, Inc., where he led development of technology converting methane gas to protein using bacteria. Previously, he was Vice President of Drug Development at Amunix, Inc. Dr. Silverman co-founded Versartis, Inc. in 2008 and participated in the founding and financing of four startup biotechnology companies (Avidia, Diartis, Siluria and Calysta). He has held positions at two public biotechnology companies, Maxygen, Inc. and Amgen, Inc. Dr. Silverman has been involved in raising over $300M in equity financing over his various companies, resulting in over $1.7B of cumulative exit value to date. Dr. Silverman earned his B.Sc. in Molecular Biology from UC San Diego and his Ph.D. in Biochemistry from Stanford University.